Celcuity Inc. · NASDAQ:CELC
Celcuity — Technical Presentation (October 2025)
22 slides from Celcuity's technical presentation, Oct 20, 2025
Slide 1: Phase 3 VIKTORIA-1 HR+/HER2-/PIK3CA WT Trial Results
Phase 3 VIKTORIA-1 HR+/HER2-/PIK3CA WT Trial Results Gedatolisib is an investigational agent and is not approved by any regulatory agency as a treatment for any indication. October 20, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to Celcuity’s business, operations, and financial condition, and include but are not limit
Slide 3: Unlocking the Potential of Treating Cancers That Involve the PAM Pathway
Unlocking the Potential of Treating Cancers That Involve the PI3K/AKT/mTOR (PAM) Pathway LARGEST ONE OF THE MOST UNTAPPED DRUG MOST IMPORTANT HIGHLY ALTERED DEVELOPMENT ONCOGENIC OF ALL SIGNALING OPPORTUNITY PATHWAYS PATHWAYS1 IN SOLID TUMORS PAM regulates key Proportion of alterations Breast and pr
Slide 4: Difficult to Safely and Comprehensively Inhibit the PAM Pathway
Difficult to Safely and Comprehensively Inhibit the PAM Pathway Optimal efficacy may require inhibition of all Class I PI3K isoforms and mTORC1 and mTORC2 MULTIPLE PATHWAY TARGETS THERAPEUTIC WINDOW FOR ORAL PROVIDE FUNCTIONAL REDUNDANCY PI3K/mTOR INHIBITORS IS NARROW If only a single target is inhi
Slide 5: Gedatolisib Has the Potential to Establish New SOC in HR+/HER2- Advanced Breast Cancer
Gedatolisib Has the Potential to Establish New SOC in HR+/HER2- Advanced Breast Cancer Gedatolisib’s differentiated MOA and PK profile as a comprehensive PAM inhibitor results in a highly potent, well 1 tolerated therapeutic that has potential to induce efficacy in PIK3CA wild-type and mutant tumors
Slide 6: Phase 3 VIKTORIA-1 PIK3CA WT Trial Results
Phase 3 VIKTORIA-1 PIK3CA WT Trial Results 6
Slide 7: VIKTORIA-1: Global Phase 3 Clinical Trial of Gedatolisib
VIKTORIA-1: Global Phase 3 Clinical Trial of Gedatolisib Arm A† HR+/HER2- ADVANCED Gedatolisib | 180mg IV once weekly, 3 weeks on, PRIMARY ENDPOINTS BREAST CANCER 1 week off PFS (BICR) STUDY 1 Palbociclib | 125mg daily, 21 days on, 7 days off Arm A vs. Arm C PIK3CA R 1:1:1 Fulvestrant | 500mg; c
Slide 8: Patient Disposition
Patient Disposition Randomized (N=392) Gedatolisib + palbociclib+ Gedatolisib + fulvestrant Fulvestrant fulvestrant (n=130) (n=131) (n=131) Received allocated treatment n=130 Received allocated treatment n=130 Received allocated treatment n=123 Discontinued study treatment n=97 Discontinued study tr
Slide 9: Patient Population Includes Significant Proportion with Aggressive Disease
Patient Population Includes Significant Proportion with Aggressive Disease 80% with liver or lung metastases and included endocrine therapy resistant patients Gedatolisib + Gedatolisib + palbociclib+ Gedatolisib + palbociclib+ Gedatolisib + fulvestrant fulvestrant fulvestrant fulvestrant fulvestrant
Slide 10: Both Co-Primary Endpoints Met: 7.3- & 5.4-month improvement in mPFS
Both Co-Primary Endpoints Met: 7.3- & 5.4-month improvement in mPFS Gedatolisib triplet and gedatolisib doublet vs. fulvestrant, BICR assessment 100 100 Geda + Palbo + Geda + fulvestrant Fulvestrant Fulvestrant fulvestrant (n=130) (n=131) 90 (n=131) 90 (n=131) 80 Median PFS, 9.3 2.0 80 Median PFS, 7
Slide 11: Gedatolisib Triplet vs. Fulvestrant
Gedatolisib Triplet vs. Fulvestrant Consistent PFS consistent across pre-specified sub-groups Gedatolisib + Palbociclib + Fulvestrant Fulvestrant Subgroup n/N mPFS, mo. n/N mPFS, mo. Hazard Ratio (90% CI) Age <65 years 39/93 9.3 74/108 1.9 0.23 (0.17-0.35) ≥65 years 20/38 9.7 15/23 2.1 0.28 (0.16-0.
Slide 12: Gedatolisib Doublet vs. Fulvestrant
Gedatolisib Doublet vs. Fulvestrant Consistent PFS consistent across pre-specified sub-groups Gedatolisib + Fulvestrant Fulvestrant Subgroup n/N mPFS, mo. n/N mPFS, mo. Hazard Ratio (90% CI) Age <65 years 52/96 5.6 74/108 1.9 0.31 (0.25-0.46) ≥65 years 17/34 7.7 15/23 2.1 0.53 (0.29-1.10) Menopause
Slide 13: PFS in Key Subgroups: Gedatolisib Triplet vs. Doublet
PFS in Key Subgroups: Gedatolisib Triplet vs. Doublet Gedatolisib + Palbociclib + Fulvestrant Gedatolisib + Fulvestrant Subgroup n/N mPFS, mo. n/N mPFS, mo. Age <65 years 39/93 9.3 52/96 5.6 ≥65 years 20/38 9.7 17/34 7.7 Menopause status Pre/perimenopause 9/28 11.1 19/37 5.6 Postmenopause 50/101 8.9
Slide 14: Interim Overall Survival Analysis Shows Favorable Trend for Gedatolisib
Interim Overall Survival Analysis Shows Favorable Trend for Gedatolisib Triplet and Doublet; Encouraging Given High Number of Patient Crossover Geda + Palbo + fulvestrant Fulvestrant Geda + fulvestrant Fulvestrant (n=131) (n=131) (n=130) (n=131) Median OS, 23.7 18.5 Median OS, NR 18.5 months (95% CI
Slide 15: Interim OS Sensitivity Analysis - Cross-Over Patients Censored
Interim OS Sensitivity Analysis - Cross-Over Patients Censored Geda + Palbo + fulvestrant Fulvestrant Geda + fulvestrant Fulvestrant (n=131) (n=131) (n=130) (n=131) Median OS, 23.7 15.8 Median OS, NR 15.8 months (95% CI) (21.4-NE) (11.7-NE) months (95% CI) (NE-NE) (11.7-NE) Adjusted HR (95% CI) 0.56
Slide 16: Duration of Response and Incremental ORR Improvement
Duration of Response and Incremental ORR Improvement for Triplet and Doublet is the Highest Reported for an ET-Based Regimen Relative to Control in 2L HR+/HER2- ABC Patients with evaluable disease, BICR assessment DURATION OF RESPONSE 100 Geda + Palbo + Gedatolisib + Duration of Response (%) 90 Fulv
Slide 17: Gedatolisib Regimens Were Generally Well-Tolerated, With Low Discontinuation Rates
Gedatolisib Regimens Were Generally Well-Tolerated, With Low Discontinuation Rates; Majority of TRAE’s Grade 1/2; Low Hyperglycemia and Diarrhea Rates SAE and Gedatolisib + palbociclib + fulvestrant Gedatolisib + fulvestrant Fulvestrant discontinuation, % (n=130) (n=130) (n=123) Pts with ≥1 SAE 11 9
Slide 18: Data Support for Gedatolisib to Become the Potential SOC Option for 2L HR+, HER2-, PIK3CA-WT ABC
Data Support for Gedatolisib to Become the Potential SOC Option for 2L HR+, HER2-, PIK3CA-WT ABC 18
Slide 19: Gedatolisib May Address a Significant Unmet Need for the Large 2nd Line Population
Gedatolisib May Address a Significant Unmet Need for the Large 2nd Line HR+/HER2- ABC Patient Population POSITIVE LARGE UNMET WELL MARKET POPULATION NEED DIFFERENTIATED DYNAMICS ~37,000 patients1 with PFS benefit is Clearly differentiated Streamlined HR+/HER2- ABC receive limited with current 2L eff
Slide 20: Upcoming Milestones
Upcoming Milestones SUBMIT Complete the submission of a New Drug Application via FDA’s RTOR NDA program for VIKTORIA-1 PIK3CA wild-type cohort indication in Q4 2025 PRESENT DATA Present additional data updates for VIKTORIA-1 PIK3CA wild-type UPDATES cohort at a major medical conference later this ye
Slide 21: Phase 1b: Geda + Palbo + Fulvestrant in 2L+ HR+/HER2- ABC Patients
Phase 1b: Geda + Palbo + Fulvestrant in 2L+ HR+/HER2- ABC Patients mPFS for PIK3CA MT patients compares favorably to currently available therapies PIK3CA-Mutated PIK3CA-Wild-Type Sub-Group Sub-Group Intermittent Intermittent All All Dose Dose N 30 11 60 15 Key Characteristics Prior CDK4/6 71% 100% 7
Slide 22: Unlocking the Potential of Treating Cancers That Involve the PI3K/AKT/mTOR Pathway
Unlocking the Potential of Treating Cancers That Involve the PI3K/AKT/mTOR Pathway